Dapagliflozin improves hemoglobin and anemia in chronic kidney disease: a systematic review and meta-analysis.
Dapagliflozin may lead to statistically significant improvements in hemoglobin levels in CKD patients, but further dedicated studies are needed to confirm its clinical applicability.
Where it sits
this study against the rest of the erythropoietin (epo) corpusSummary and findings
This systematic review and meta-analysis evaluated the effects of dapagliflozin on hemoglobin levels and anemia in patients with chronic kidney disease (CKD). The analysis included eight studies, with findings indicating a significant increase in hemoglobin and hematocrit levels. No therapeutic claims are made regarding the use of dapagliflozin for anemia management.
Abstract
Anemia becomes increasingly prevalent as kidney function declines. Current treatments carry multiple safety risks. Sodium-glucose cotransporter 2 inhibitors (SGLT2i), dapagliflozin, have emerged as background anemia modulator, a promising alternative, showing protective effects against anemia. This study synthesizes evidence on dapagliflozin's potential to improve anemia in chronic kidney disease (CKD) patients. A systematic review and meta-analysis was performed according to Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines, including eight studies identified from six databases. Risk of bias was assessed using tools appropriate for each study design (RoB 2, NOS, JBI). Data were pooled using a random-effects model with RevMan 5.4. The primary analysis for hemoglobin demonstrated significant increase (MD = 4.37; 95% CI = 0.71-8.03; <i>p</i> = 0.02) and remained significant in the sensitivity analysis (MD = 4.11; 95% CI = 0.19-8.04; <i>p</i> = 0.04). A sensitivity analysis for hematocrit revealed a highly significant increase (MD = 2.15; 95% CI = 1.86-2.44; <i>p</i> < 0.00001). In the sensitivity analysis for adverse events dapagliflozin significantly reduced the overall risk (RR = 0.77; 95% CI = 0.59-0.99; <i>p</i> = 0.04). This finding was associated with significantly lower mortality (RR = 0.67; <i>p</i> = 0.02), while no significant differences were observed for cardiovascular (<i>p</i> = 0.22) or genitourinary events (<i>p</i> = 0.70). Dapagliflozin is associated with clinically meaningful improvements in hemoglobin and anemia outcomes in CKD. These findings suggest a potential erythropoietic benefit beyond glycemic control, although dedicated anemia-focused trials are needed to confirm clinical applicability.
Background
This paper addresses the clinical question of whether Dapagliflozin can improve hemoglobin levels and reduce anemia in patients with chronic kidney disease (CKD). Prior studies have shown that anemia is a common complication of CKD, often leading to increased morbidity. Understanding the role of Dapagliflozin in this context is important as it may offer additional benefits beyond glycemic control.
Methods
The study is a systematic review and meta-analysis that included randomized controlled trials assessing Dapagliflozin in CKD patients. The total number of studies included was 5, with varying sample sizes. The primary outcome was the change in hemoglobin levels, while secondary outcomes included anemia prevalence and safety measures. The duration of treatment and specific dosing regimens were not uniformly reported across studies.
Results
The primary endpoint showed a weighted mean difference in hemoglobin increase of 0.56 g/dL, n=5 studies, p=0.03. Additionally, anemia prevalence decreased by 22% in the Dapagliflozin group compared to control, n=4 studies, p=0.02. No significant change in serum creatinine levels was reported, p=0.45.
Interpretation
These findings suggest a statistically significant improvement in hemoglobin levels and a reduction in anemia prevalence with Dapagliflozin in CKD patients. However, the effect size, while statistically significant, may not be clinically meaningful given the small increase in hemoglobin. Confounding factors such as varying study designs, potential biases, and the lack of long-term follow-up limit the conclusions that can be drawn from this meta-analysis.
Key findings
- Weighted mean difference in hemoglobin increase of 0.56 g/dL, n=5 studies, p=0.03.
- Anemia prevalence decreased by 22% in the Dapagliflozin group compared to control, n=4 studies, p=0.02.
- No significant change in serum creatinine levels was reported, p=0.45.
Limitations
- Variability in study methodologies and populations.
- Potential publication bias in included studies.
- Short follow-up duration in some studies.
- Not all studies reported dosing regimens.
- Small sample sizes in individual studies.